Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder.
Quantitative urinary immunocytology with our monoclonal antibody (mab) 486p 3/12 proved to be valuable for diagnostic use in bladder-cancer patients' urine, especially in the followup of patients with superficial bladder carcinoma. To evaluate the use of other monoclonal antibodies in bladder cancer, we compared 15 mabs directed against bladder-tumor-associated antigens from seven research groups in a broad panel of cellular and tissue specimens (bladder tumor, prostatic adenoma, and kidney stone). Quantitative evaluation was done in cytocentrifuged preparations and tissue specimens. None of the 15 mabs was bladder-tumor-specific. All 15 stained normal urothelium to some extent and six stained granulocytes. Each of the 15 seemed to identify a different cellular antigen, as can be clearly demonstrated by the staining pattern of different regions in the normal kidney. The sensitivity of quantitative urinary immunocytology in bladder-tumor patients can be improved by using a panel, rather than one mab in bladder-tumor patients, but specificity decreases simultaneously. A main reason for the poor specificity of quantitative urinary immunocytology with all 15 mabs is that false-positive results are obtained with all mabs in kidney-stone patients. Our quantitative urinary immunocytology method is a general tool for the diagnostic use of all mabs in bladder-tumor patients. Mabs that have a high sensitivity might be useful in the followup of patients with superficial bladder carcinoma. None of the 15 mabs (because of their poor specificity) seems to be helpful in quantitative urinary immunocytology for screening a population for bladder carcinoma.
Huland
E
E
Klinikum Steglitz, Free University of Berlin, Germany.
Huland
H
H
Meier
T
T
Baricordi
O
O
Fradet
Y
Y
Grossman
H B
HB
Hodges
G M
GM
Messing
E M
EM
Schmitz-Draeger
B J
BJ
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology; D002295:Carcinoma, Transitional Cell / Q000276:immunology* / Q000473:pathology / Q000652:urine; D002460:Cell Line; D006098:Granulocytes / Q000276:immunology / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007668:Kidney / Q000276:immunology / Q000473:pathology; D007669:Kidney Calculi / Q000276:immunology / Q000473:pathology; D008297:Male; D011470:Prostatic Hyperplasia / Q000276:immunology / Q000473:pathology; D001743:Urinary Bladder / Q000276:immunology / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000473:pathology / Q000652:urine
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm